Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | CCR5 | P51681 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2795250 | 0.99 | HTR2A (0.46) | HTR2ACCR5OPRM1HSD11B1UBE2M | |
| Hydrochloric Acid SCHEMBL2794028 | 0.99 | HTR2A (0.46) | HTR2ACCR5OPRM1HSD11B1UBE2M | |
| Hydrochloric Acid SCHEMBL2797233 | 0.93 | HTR2A (0.47) | HTR2ACCR5HSD11B1PTGDR2 | |
| Hydrochloric Acid SCHEMBL2797514 | 0.91 | HTR2A (0.56) | HTR2AOPRM1 | |
| Hydrochloric Acid SCHEMBL2793463 | 0.90 | HTR2A (0.49) | HTR2AOPRM1UBE2MDCUN1D1PTGDR2 | |
| Hydrochloric Acid SCHEMBL2791123 | 0.89 | HTR2A (0.44) | HTR2ACCR5HSD11B1PTGDR2 | |
| Hydrochloric Acid SCHEMBL2793291 | 0.88 | HTR2A (0.48) | HTR2APTGDR2 | |
| Hydrochloric Acid SCHEMBL2796669 | 0.88 | HTR2A (0.43) | HTR2ACCR5PTGDR2 | |
| SCHEMBL2795154 | 0.85 | HTR2A (0.51) | HTR2ACCR5OPRM1UBE2MDCUN1D1 | |
| SCHEMBL2791118 | 0.85 | THRB (0.45) | HTR2ACCR5OPRM1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| EP-2164829-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150089-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | PDF, PEPD, DPEP1 | HTR2A 4650/4885CCR5 3574/4885OPRM1 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.